The company's share price Equillium, Inc.
Equillium is a biotech company developing drugs to treat autoimmune and inflammatory diseases. Its stock price is highly volatile and driven by news about the progress of its clinical trials.
Equillium is a biotech company developing drugs to treat autoimmune and inflammatory diseases. Its stock price is highly volatile and driven by news about the progress of its clinical trials.
Equillium is a biopharmaceutical company developing innovative treatments for severe autoimmune and inflammatory diseases. We classify it as "Immune Pharmaceuticals." The chart below illustrates the overall dynamics of this complex yet important field of medicine.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Equillium shares compare to sentiment in the biotech sector.
For Equillium, Inc., a biopharmaceutical company, daily price change is a measure of the high volatility typical of the sector. This metric reflects the market's reaction to drug development news and is critical to the risk assessment formulas at System.GURU.Markets.
For Equillium, Inc., a biopharmaceutical company, daily price change is a measure of the high volatility typical of the sector. This metric reflects the market's reaction to drug development news and is critical to the risk assessment formulas at GURU.Markets.
Equillium is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
For Equillium, Inc., the year-over-year trend is a story of developing drugs for the treatment of autoimmune and inflammatory diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate, itolizumab, could offer a new approach to treating conditions such as graft-versus-host disease.
Equillium, Inc. is a clinical-stage biotech company developing drugs for the treatment of autoimmune and inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Equillium is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Equillium is a clinical-stage biotech company targeting autoimmune diseases. Its monthly performance is entirely dependent on the results of clinical trials of its lead drug, itumilimab. Data across various indications is generating strong investor reaction.
Equillium, Inc. is a clinical-stage biotechnology company developing new treatments for severe autoimmune and inflammatory diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it's possible to assess the progress of its targeted drugs, which target key immune system pathways, in clinical trials.
Equillium is a biotech company working in the field of immunology. Its shares are preoccupied with anticipation of clinical trial results. Their monthly performance is completely disconnected from the broader market and driven by drug development news, as the chart clearly illustrates, showing reactions to events rather than general trends.
Equillium, Inc., a clinical-stage biotech developing therapies for autoimmune diseases, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials and regulatory decisions, reflecting the risks and hopes in this complex area of medicine.
Equillium is a biotech company focused on immunology and autoimmune disease treatment. The chart below allows us to separate its clinical data-driven volatility from the broader volatility of its sector, highlighting the unique nature of its scientific journey.
Equillium is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that Equillium's performance is largely uncorrelated with the market, moving on its own unique news.
Equillium's stock chart is a financial map of the fight against autoimmune diseases. This biotech company's market cap reflects the hopes for its drugs targeting key immune system pathways. Its dynamics are a barometer of progress in clinical trials for conditions such as graft-versus-host disease and lupus nephritis.
Equillium's market share in the immunology sector reflects its focus on treating severe autoimmune and inflammatory diseases. Its market share is based on the potential of its key drug candidates, betting that its developments will offer new solutions to complex medical problems.
Equillium is a biotech company focused on treating severe autoimmune and inflammatory diseases. The chart below shows the overall market capitalization of this cutting-edge sector. Its dynamics reflect investors' enormous hopes for the development of new, more effective treatments.
Equillium is a biopharmaceutical company developing drugs to treat severe autoimmune and inflammatory diseases. Its market capitalization reflects the potential of its scientific research. The chart below shows the economic weight of companies at the forefront of immunology.
Equillium is a biopharmaceutical company. Its book value represents its clinical research capital. The chart below shows its financial resources, not its manufacturing facilities. Its level is an indicator of its ability to fund drug development for autoimmune diseases.
Equillium is a clinical-stage biotech company developing therapeutics for immune diseases. Its value lies in its scientific platform and patents. Its share of tangible assets will be minimal, which is typical for R&D companies whose primary capital is intellectual property.
Equillium is a clinical-stage biotech company. Its value is created in labs, not factories. It's a "lightweight" model based on intellectual capital. The chart below shows how much the biopharmaceutical industry relies on tangible assets versus intellectual capital.
Equillium's balance sheet represents capital focused on developing drugs to treat severe autoimmune and inflammatory diseases by targeting the CD6-ALCAM signaling pathway. The book value chart shows the resources devoted to this innovative therapeutic target.
Equillium is a biotech company developing drugs to treat severe autoimmune diseases. Its balance sheet represents cash flow for research. Its market capitalization is an assessment of its scientific approach and the potential of its lead drug. The chart reflects how the market weighs the chances of success in treating conditions with significant unmet need.
Equillium is a clinical-stage biotech company focused on treating autoimmune diseases. Its value lies in its scientific developments. The chart clearly demonstrates the premium investors are paying for the potential of its drugs, which is many times greater than the value of its tangible assets.
Equillium is a biotech company developing therapies for severe autoimmune and inflammatory diseases. The chart shows how the market values a company targeting complex medical problems. Equillium's market capitalization is based not on its assets but on the potential of its drug candidates to improve patients' lives, which is a risky bet.
Equillium is a clinical-stage biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Debt instruments for such companies are a way to extend financial resources to complete key clinical trials, as reflected by the financial strategy shown in this chart.
Equillium is a biopharmaceutical company developing drugs to treat severe autoimmune and inflammatory diseases. Their research targets key immune pathways. The chart shows the financial standards for the biotech sector, against which Equillium raises capital to advance its candidates through the expensive stages of clinical trials.
Equillium is a biotech company focused on immunology and autoimmune disease treatment. Developing such complex drugs requires significant investment. This chart shows the company's debt-to-equity ratio, giving investors an idea of the company's financial vulnerability in the event of delays or failures in clinical trials.
Equillium's development of drugs for autoimmune diseases targets a large and growing market. This chart shows how the biotech sector as a whole funds its R&D. It allows us to assess how Equillium's financial model, with its specific approach to immunomodulation, differs from other companies in this competitive field.
Equillium is a biopharmaceutical company focused on treating severe autoimmune and inflammatory diseases. Clinical trials in this field are lengthy and expensive. The chart illustrates how their financial structure and debt load compare to the overall risk and leverage levels in innovative industries.
This chart for Equillium, Inc., a clinical-stage biopharmaceutical company specializing in the treatment of autoimmune diseases, reflects investor expectations. Its value is determined not by current revenue, but by the potential of its scientific developments to become effective therapies.
This metric represents the average valuation for the biotech sector in which Equillium operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding autoimmune disease treatments.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Its valuation depends on the success of clinical programs in this complex area of medicine. This chart shows investors' overall risk appetite. It helps understand how news about Equillium's clinical trials impacts its valuation relative to the overall trend in the immunology sector.
Equillium is a biotech company developing new treatments for severe autoimmune and inflammatory diseases by modulating the immune response. Its future depends on the success of its lead drug in clinical trials. This chart reflects investor expectations regarding the potential of its therapy for treating conditions such as acute graft-versus-host disease.
%20P%2FE%20Equillium%2C%20Inc.&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Equillium-Inc. "Chart of the company's future (projected) P/E Equillium, Inc.")
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. The company targets key immune system signaling pathways. This chart reflects expectations for the biotech sector, providing an opportunity to assess how the market views Equillium's scientific approach and development pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Their work focuses on modulating the immune system. This chart of general expectations reflects investor sentiment toward biotech. Market optimism and risk appetite allow companies like Equillium to raise capital to conduct complex and expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Equillium is a clinical-stage biotech company developing therapies for severe autoimmune and inflammatory diseases. This chart shows the cost of advancing drugs through clinical trials. Future profitability depends entirely on the success of these trials and potential partnerships with major pharmaceutical companies.
Kartoon Studios Inc., formerly Genius Brands, is a children's entertainment production and distribution company. Its profitability depends on the creation of popular characters and licensing deals. This chart reflects the highly competitive world of children's media, where a single successful animated series can generate huge revenues, but most projects fail to achieve such success.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Currently in clinical trials, its value is determined by the potential of its leading developments. This is an example of how innovation in medicine can lead to breakthroughs, regardless of the economic cycle.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Its revenue forecast depends on the success of clinical trials and potential partnerships. This chart reflects analyst expectations regarding the potential of its immunology developments and the company's ability to bring them to market.
%20profit%20of%20the%20company%20Equillium%2C%20Inc.&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Equillium-Inc. "Graph of future (projected) profit of the company Equillium, Inc.")
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Its therapy targets the key immune pathway CD6-ALCAM. This chart shows profitability projections for the biotech sector. It reflects the high expectations and risks associated with developing new treatments for complex immune system diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
Equillium is a biotech company focused on immunology. It is developing treatments for severe autoimmune diseases. Its future depends on successful research. The earnings forecast chart presented here influences investors' overall risk appetite, which is critical for raising capital for lengthy and costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Without any commercial products, its revenue comes from partnerships. The valuation shown in this chart is based on investors' faith in its scientific approach and the potential of its drug candidates to address unmet medical needs.
Equillium, Inc. is a clinical-stage biopharmaceutical company developing novel treatments for severe autoimmune and inflammatory diseases by targeting key immune pathways. This chart shows the average valuation in the sector, providing an indication of the market's perception of Equillium's revenue potential.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Its research focuses on modulating the immune response. This chart, reflecting the average estimated real income, clearly highlights how biotech investments are betting on scientific breakthroughs rather than on current cash flows.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. This chart shows how investors assess the future potential of its lead candidate. This assessment is based on expectations for successful clinical trials, which could lead to the development of a new treatment.
%20P%2FS%20Equillium%2C%20Inc.&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Equillium-Inc. "The graph of the company's future (projected) P/S Equillium, Inc.")
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Its therapies are aimed at modulating the immune response. This chart shows the premium investors are willing to pay for Equillium's future sales, reflecting the high potential of its developments in the complex field of immunology.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
Investor optimism about future earnings hinges on progress in treating autoimmune diseases. Equillium develops drugs that modulate the immune system to stop it from attacking the body's own tissues. The potential of their therapies to treat a wide range of diseases supports the belief that biotechnology can address these complex conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
Equillium is a clinical-stage biopharmaceutical company focused on the treatment of severe autoimmune and inflammatory diseases. Currently, its revenue is generated not from product sales but from licensing agreements and partnerships. This chart reflects the financial results of its research activities.
Equillium is a biotech company developing new treatments for severe autoimmune and inflammatory diseases by targeting key immune system pathways. This chart shows total revenue in the immunology pharmaceutical sector. It highlights a vast and highly competitive market, where Equillium is seeking to carve out a niche with its novel approach.
Equillium is a clinical-stage biopharmaceutical company developing drugs for the treatment of severe autoimmune and inflammatory diseases. Its future depends on the results of clinical trials. This economic outlook affects the overall investment environment for biotech companies, which require significant capital for research.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Its future depends on the results of clinical trials. The chart shows analysts' speculative revenue forecasts, which are a bet on the company's ability to offer effective treatments for these complex conditions.
%20sales%20of%20the%20company%20Equillium%2C%20Inc.&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Equillium-Inc. "Schedule of future (projected) sales of the company Equillium, Inc.")
Equillium is a biotechnology company developing drugs to treat severe autoimmune and inflammatory diseases by modulating the immune response. The company's success depends on the results of clinical trials. This chart displays projected sales for the entire immunological pharmaceutical segment, demonstrating overall growth expectations for this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
Equillium is a clinical-stage biotechnology company developing therapies for severe autoimmune and inflammatory diseases. Its valuation depends on the potential of its developments. This general economic activity profile influences the investment environment and investor willingness to finance long-term, risky biotechnology projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Equillium is a biotech company developing therapies for severe autoimmune and inflammatory diseases. This metric reflects its financial progress through the clinical trial stage. It demonstrates the level of R&D investment required to bring a new class of drugs to market and achieve commercial success.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. Being in the clinical stage, its financial metrics reflect its investment in R&D. This chart provides insight into the company's operating model and cost structure compared to other immunology companies.
Equillium is a clinical-stage biopharmaceutical company developing therapies for severe autoimmune and inflammatory diseases. Their lead drug targets a key immune pathway. Their future depends on research results. This overall profitability curve is influenced by the overall investment climate and the availability of funding in the biotech sector.
Equillium is a clinical-stage biotech company focused on treating severe autoimmune and inflammatory diseases. Its staff consists primarily of scientists and clinicians. This chart illustrates how the company is growing its team to conduct complex clinical trials and advance its drug candidates.
Equillium develops treatments for severe autoimmune and inflammatory diseases. This chart shows the percentage of leading immunologists and clinicians in this complex field of medicine that the company attracts. Its team is working on developing therapies that can restore balance to the immune system.
Equillium, Inc. is a biotechnology company developing drugs to treat severe autoimmune and inflammatory diseases. This chart shows overall employment in the immunology research sector. It illustrates the high demand for new treatments for conditions in which the immune system attacks the body, a focus for Equillium.
Equillium is a biotech company developing therapies for severe autoimmune and inflammatory diseases. Its goal is to restore balance to the immune system. This chart illustrates the dynamics of the labor market, where the science-intensive biotech sector plays a key role in innovation. The growth of such companies signifies progress in the fight against complex chronic diseases.
Equillium, Inc. is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. This chart demonstrates a high valuation of intellectual capital. As with most biotech R&D companies, the valuation per employee is very high because the market evaluates the potential of unique developments rather than current operating metrics.
%20of%20the%20company%20Equillium%2C%20Inc.%20(EQ)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Equillium-Inc.-EQ "Chart of market capitalization per employee (in thousands of dollars) of the company Equillium, Inc. (EQ)")
Equillium is a biotech company focused on treating severe autoimmune and inflammatory diseases. Their valuation is determined by the potential of their clinical programs. This chart shows how highly the market values their scientific approach and development pipeline. The high market capitalization per employee reflects investors' expectations for success in developing new therapeutics.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Equillium, Inc. is a clinical-stage biopharmaceutical company developing a therapy for severe autoimmune diseases. Its valuation is dependent on the results of clinical trials. This metric reflects a typical biotech situation, where a small team of scientists is working on a project with the potential to generate billions in revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Equillium is a clinical-stage biotech company focused on treating severe autoimmune and inflammatory diseases. It's an R&D company. This metric reflects their ongoing investment in research: it shows the net loss (expenses for clinical trials) per employee.
%20Chart%20Equillium%2C%20Inc.%20(EQ)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Equillium-Inc.-EQ "Company Profit Per Employee (in thousands of dollars) Chart Equillium, Inc. (EQ)")
Equillium is a clinical-stage biotech focused on treating autoimmune diseases. Like most biotechs in the R&D phase, this metric is currently negative. This chart provides a guide to the future. Success will depend on whether their research team can create a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Equillium (EQ) is a biotech company specializing in the treatment of autoimmune and inflammatory diseases. They are in clinical development. This chart shows that their current business is R&D expenses. Their profit per employee is negative, as their entire research team is working on future products.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
For Equillium, a biotech company developing drugs to treat autoimmune diseases, this chart shows progress in clinical trials. Revenue per employee likely comes from partnerships, and its growth depends on the success of bringing new drugs to market.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Equillium-Inc.-EQ "Sales chart per company employee Equillium, Inc. (EQ)")
Equillium is a biopharmaceutical company developing drugs for the treatment of severe autoimmune and inflammatory diseases. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their scientific team is in advancing their candidates to clinical trials compared to other biotech companies in the field of immunology.
Equillium (EQ) is a clinical-stage biopharmaceutical company developing therapies for severe autoimmune and inflammatory diseases. Currently, its staff consists entirely of researchers. This metric is critically important for EQ: it's at zero. Future growth will depend on either successful licensing of their candidates or partnerships.
Equillium is a biotech company specializing in the treatment of severe autoimmune and inflammatory diseases. Its future depends on clinical data. This chart reflects investor bets that its drug candidates will fail to prove effective in this challenging therapeutic area, leading to trial failure.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Equillium-Inc.-EQ "Short Shares Chart for the Company Equillium, Inc. (EQ)")
Equillium (EQ) is a biopharmaceutical company focused on developing drugs to treat severe autoimmune and inflammatory diseases. This chart summarizes the bearish bets on the immunobiotech sector. It demonstrates the overall market pessimism regarding the success of clinical trials of fundamentally new, unproven biological targets.
Equillium (EQ) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like EQ in order to move into safer assets.
Equillium (EQ) is a biotech company operating in the competitive field of immunology. This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive trial data or "oversold" on news of delays.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Equillium-Inc.-EQ "RSI 14 indicator chart for the company's stock Equillium, Inc. (EQ)")
Equillium (EQ) is a biotech company that boosts immunity. They develop antibodies (anti-CD6) to treat autoimmune diseases (such as graft-versus-host disease, or GvHD). The pharma-immune (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is EQ's growth due to their R&D, or is the entire biotech sector "overheated"?
Equillium (EQ) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Equillium (EQ) is a biopharmaceutical company developing drugs to treat severe autoimmune and inflammatory diseases by modulating the immune system (targeting CD6). This chart shows the speculative average price target from analysts based on their assessment of this R&D portfolio.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EQ-Equillium-Inc. "A chart showing analyst consensus forecasts for the expected stock price. EQ (Equillium, Inc.)")
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. This chart shows the difference between the current price and the analyst consensus estimate. It reflects their view on the clinical potential of the company's R&D portfolio and the risks associated with development.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EQ-Equillium-Inc. "A chart showing the difference between the consensus forecast and the actual stock price. EQ (Equillium, Inc.)")
Equillium (EQ) is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases (such as graft-versus-host disease). This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe R&D success in this complex field is possible.
Equillium (EQ) is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. This chart shows the overall risk appetite. For Equillium, a high-risk clinical-stage company, overall market optimism is critical to raising the capital needed to fund long-term clinical trials.
Equillium (EQ) is a clinical-stage biotech focused on immunology. They are developing drugs to suppress the overactive immune system that causes autoimmune diseases (lupus, asthma). This graph represents pure R&D betting. Its valuation reflects the market's faith in their scientific platform (CD6) and the data from their early (and very risky) clinical trials.
Equillium is a biotech company specializing in developing drugs to treat severe autoimmune and inflammatory diseases. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Equillium, which is developing breakthrough technology, compares to the average.
Equillium is a biotech company developing drugs to treat severe autoimmune and inflammatory diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific play with a multi-asset pipeline compares to overall economic trends and investor risk appetite.
